- Home
- UAN vs BCAX Comparison
UAN vs BCAX Comparison
Compare UAN & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- BCAX
- Stock Information
- Founded
- UAN 2007
- BCAX 2018
- Country
- UAN United States
- BCAX United States
- Employees
- UAN N/A
- BCAX N/A
- Industry
- UAN Agricultural Chemicals
- BCAX
- Sector
- UAN Industrials
- BCAX
- Exchange
- UAN Nasdaq
- BCAX NYSE
- Market Cap
- UAN 799.2M
- BCAX 670.9M
- IPO Year
- UAN 2011
- BCAX 2024
- Fundamental
- Price
- UAN $75.00
- BCAX $13.03
- Analyst Decision
- UAN
- BCAX Strong Buy
- Analyst Count
- UAN 0
- BCAX 6
- Target Price
- UAN N/A
- BCAX $34.20
- AVG Volume (30 Days)
- UAN 23.2K
- BCAX 603.5K
- Earning Date
- UAN 04-28-2025
- BCAX 03-27-2025
- Dividend Yield
- UAN 8.98%
- BCAX N/A
- EPS Growth
- UAN N/A
- BCAX N/A
- EPS
- UAN 5.76
- BCAX N/A
- Revenue
- UAN $525,323,999.00
- BCAX N/A
- Revenue This Year
- UAN N/A
- BCAX N/A
- Revenue Next Year
- UAN N/A
- BCAX N/A
- P/E Ratio
- UAN $12.99
- BCAX N/A
- Revenue Growth
- UAN N/A
- BCAX N/A
- 52 Week Low
- UAN $62.94
- BCAX $11.10
- 52 Week High
- UAN $88.94
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- UAN 42.92
- BCAX N/A
- Support Level
- UAN $74.85
- BCAX N/A
- Resistance Level
- UAN $75.99
- BCAX N/A
- Average True Range (ATR)
- UAN 1.46
- BCAX 0.00
- MACD
- UAN 0.08
- BCAX 0.00
- Stochastic Oscillator
- UAN 49.05
- BCAX 0.00
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.